The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Cytochrome P450 variations in different ethnic populations
Abstract
INTRODUCTION: Variability of drug response is an important consideration in clinical medicine. A major determinant of drug response variability is hepatic cytochrome P450 oxidase (CYP450)-mediated drug metabolism. Advances in genetics permits genotyping large numbers of patients to identify single nucleotide polymorphisms (SNPs) which may result in variant CYP450 enzyme expression and/or activity. New SNPs with functional impacts are constantly being identified which further explain variability in CYP450 phenotype. AREAS COVERED: The racial/ethnic distribution of selected CYP450 (CYP1A2, P2C8/9/19, 2D6 and 3A4/5) SNPs are reviewed with an emphasis on the agreement between genotype and phenotype. The reader will gain insight into the SNP distribution by racial/ethnic group and the corresponding relationship between important, highly prevalent, SNPs and their impact on metabolic phenotype. EXPERT OPINION: Racial/ethnic differences in metabolic phenotype can be explained by differences in SNP distribution. However, overlap in substrate specificity, linkage disequilibrium and previously unidentified SNPs have made phenotypic characterization difficult for CYP3A4/5 and 2C8/9. Studies utilizing newly identified, highly prevalent, racially stratified SNPs and their impact on CYP isoform-specific metabolism will provide new answers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Shuldiner, A. R. (2009) · JAMA · doi:10.1001/jama.2009.1232 · Cited by 1,505
Nelson, D. R. (2009) · Human Genomics · doi:10.1186/1479-7364-4-1-59 · Cited by 1,014
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Molecular Basis of Ethnic Differences in Drug Disposition and Response
Xie, H.-G., Kim, R. B., Wood, A. J., & Stein, C. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.815 · Cited by 600
Trenk, D., Hochholzer, W., Fromm, M. F., Chialda, L.-E., Pahl, A., Valina, C. M., Stratz, C., Schmiebusch, P., Bestehorn, H.-P., Büttner, H. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.056 · Cited by 540
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
Wang, D., Guo, Y., Wrighton, S. A., Cooke, G. E., & Sadee, W. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.28 · Cited by 505
Coffee, CYP1A2 genotype, and risk of myocardial infarction
Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., & Campos, H. (2006) · JAMA · doi:10.1001/jama.295.10.1135 · Cited by 490 · cited 1×
“have designated the CYP1A2*1F variant as the -163A allele (-163C > A) making the -163C allele CYP1A2*1A while others have adopted an opposite nomenclature [16,17].”
BackgroundSibbing, D., Stegherr, J., Latz, W., Koch, W., Mehilli, J., Dorrler, K., Morath, T., Schomig, A., Kastrati, A., & von Beckerath, N. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehp041 · Cited by 418
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
Ingelman-Sundberg, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0819-z · Cited by 353
CYP3A Variation and the Evolution of Salt-Sensitivity Variants
Thompson, E. E., Kuttab-Boulos, H., Witonsky, D., Yang, L., Roe, B. A., & Di Rienzo, A. (2004) · The American Journal of Human Genetics · doi:10.1086/426406 · Cited by 331
Schoedel, K. A., Hoffmann, E. B., Rao, Y., Sellers, E. M., & Tyndale, R. F. (2004) · Pharmacogenetics · doi:10.1097/00008571-200409000-00006 · Cited by 315
Genetic Variability in CYP3A5 and its Possible Consequences
Xie, H.-G., Wood, A. J., Kim, R. B., Stein, C. M., & Wilkinson, G. R. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.243.29833 · Cited by 302
CYP2B6: New Insights into a Historically Overlooked Cytochrome P450 Isozyme
Wang, H., & Tompkins, L. M. (2008) · Current Drug Metabolism · doi:10.2174/138920008785821710 · Cited by 299
Preissner, S., Kroll, K., Dunkel, M., Senger, C., Goldsobel, G., Kuzman, D., Guenther, S., Winnenburg, R., Schroeder, M., & Preissner, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp970 · Cited by 274
Bauer, T., Bouman, H. J., van Werkum, J. W., Ford, N. F., ten Berg, J. M., & Taubert, D. (2011) · BMJ · doi:10.1136/bmj.d4588 · Cited by 266
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Li‐Wan‐Po, A., Girard, T., Farndon, P., Cooley, C., & Lithgow, J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03578.x · Cited by 262
Gunes, A., & Dahl, M.-L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.625 · Cited by 256
Elens, L., Bouamar, R., Hesselink, D. A., Haufroid, V., van der Heiden, I. P., van Gelder, T., & van Schaik, R. H. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165613 · Cited by 245
Zhou, S.-F., Yang, L.-P., Zhou, Z.-W., Liu, Y.-H., & Chan, E. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9127-y · Cited by 238
Giusti, B., Gori, A. M., Marcucci, R., Saracini, C., Sestini, I., Paniccia, R., Buonamici, P., Antoniucci, D., Abbate, R., & Gensini, G. F. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.048 · Cited by 225
Hofmann, M. H., Blievernicht, J. K., Klein, K., Saussele, T., Schaeffeler, E., Schwab, M., & Zanger, U. M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133306 · Cited by 210
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales
Sistonen, J., Fuselli, S., Palo, J. U., Chauhan, N., Padh, H., & Sajantila, A. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32831ebb30 · Cited by 200
Drugs as CYP3A Probes, Inducers, and Inhibitors
Liu, Y.-T., Hao, H.-P., Liu, C.-X., Wang, G.-J., & Xie, H.-G. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530701690374 · Cited by 196
Henningsson, A., Marsh, S., Loos, W. J., Karlsson, M. O., Garsa, A., Mross, K., Mielke, S., Viganò, L., Locatelli, A., Verweij, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1152 · Cited by 188
Oscarson, M., McLellan, R. A., Gullstén, H., Agúndez, J. A. G., Benı́tez, J., Rautio, A., Raunio, H., Pelkonen, O., & Ingelman-Sundberg, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01364-2 · Cited by 181
Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., & Ingelman-Sundberg, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.659 · Cited by 181
Interethnic and Intraethnic Variability of CYP2C8 and CYP2C9 Polymorphisms in Healthy Individuals
García‐Martín, E., Martínez, C., Ladero, J. M., & Agúndez, J. A. G. (2006) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256440 · Cited by 157
Diczfalusy, U., Miura, J., Roh, H., Mirghani, R. A., Sayi, J., Larsson, H., Bodin, K., Allqvist, A., Jande, M. B., Jong-Wook, K., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f50ee9 · Cited by 152
Cytochrome P450 2C8 Pharmacogenetics: A Review of Clinical Studies
Daily, E. B., & Aquilante, C. L. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.82 · Cited by 148
Yaeger, R. D., Avila-Bront, A., Abdul, K., Nolan, P. C., Grann, V. R., Birchette, M. G., Choudhry, S., Burchard, E. G., Beckman, K. B., Gorroochurn, P., et al. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2505 · Cited by 142
Hesselink, D. A., van Schaik, R. H. N., van Agteren, M., de Fijter, J. W., Hartmann, A., Zeier, M. G., Budde, K., Kuypers, D. R. J., Pisarski, P., Meur, Y. L., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f75f88 · Cited by 140
Murray, M. T. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.7.0001 · Cited by 139
Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6
Mo, S., Liu, Y.-H., Duan, W., Wei, M. Q., Kanwar, J. R., & Zhou, S.-F. (2009) · Current Drug Metabolism · doi:10.2174/138920009789895534 · Cited by 137
Polymorphisms of human cytochrome P450 2C9 and the functional relevance
Zhou, S.-F., Zhou, Z.-W., & Huang, M. (2009) · Toxicology · doi:10.1016/j.tox.2009.08.013 · Cited by 134
Westlind-Johnsson, A., HERMANN, R., Huennemeyer, A., Hauns, B., Lahu, G., Nassr, N., Zech, K., Ingelman‐Sundberg, M., & von Richter, O. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.015 · Cited by 128
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour
Tricker, A. R. (2003) · Toxicology · doi:10.1016/s0300-483x(02)00513-9 · Cited by 127
Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity
Neafsey, P. J., Ginsberg, G., Hattis, D. B., & Sonawane, B. R. (2009) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937400903158342 · Cited by 121
Joerger, M., Huitema, A. D. R., van den Bongard, H. J. G. D., Schellens, J. H. M., & Beijnen, J. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2069 · Cited by 120
Laika, B., Leucht, S., Heres, S., Schneider, H., & Steimer, W. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.32 · Cited by 110
CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic Dosing
Scott, S. A., Jaremko, M., Lubitz, S. A., Kornreich, R., Halperin, J. L., & Desnick, R. J. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.71 · Cited by 100
Bergmann, T. K., Brasch‐Andersen, C., Gréen, H., Mirza, M. R., Pedersen, R. S., Nielsen, F., Skougaard, K., Wihl, J., Keldsen, N., Damkier, P., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.19 · Cited by 100
Cai, W.-M., Nikoloff, D. M., Pan, R. M.-D., et al. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500378 · Cited by 95
Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2
Han, X., Ouyang, D., Chen, X., Shu, Y., Jiang, C., Tan, Z., & Zhou, H. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01686.x · Cited by 92
Grabar, P. B., Rozman, B., Tomšič, M., Šuput, D., Logar, D., & Dolžan, V. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0498-2 · Cited by 89
Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes
Singh, M. S., Francis, P. A., & Michael, M. (2010) · The Breast · doi:10.1016/j.breast.2010.11.003 · Cited by 89
Genetic determinants of platelet response to clopidogrel
Kubica, A., Koziński, M., Grześk, G., Fabiszak, T., Navarese, E. P., & Goch, A. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0611-8 · Cited by 89
Mwenifumbo, J. C., Koudsi, N. A., Ho, M., Zhou, Q., Hoffmann, E. B., Sellers, E. M., & Tyndale, R. F. (2008) · Human Mutation · doi:10.1002/humu.20698 · Cited by 87
Mirghani, R. A., Sayi, J., Aklillu, E., Allqvist, A., Jande, M. B., Wennerholm, A., Eriksen, J., Herben, V. M. M., Jones, B., Gustafsson, L. L., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230411.89973.1b · Cited by 85
INTERINDIVIDUAL DIFFERENCES IN NICOTINE METABOLISM AND GENETIC POLYMORPHISMS OF HUMAN CYP2A6
Nakajima, M., Kuroiwa, Y., & Yokoi, T. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120015696 · Cited by 73
Cytochrome P450 3A Polymorphisms and Immunosuppressive Drugs
Thervet, É., Legendre, C. M., Beaune, P. H., & Anglicheau, D. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.1.37 · Cited by 60
Influence of CYP2C9 Genotype on Warfarin Dose Among African–Americans and European–Americans
Limdi, N. A., Goldstein, J. A., Blaisdell, J., Beasley, T. M., Rivers, C., & Acton, R. T. (2007) · Personalized Medicine · doi:10.2217/17410541.4.2.157 · Cited by 56
Pharmacogenomics ofCYP3A: Considerations for HIV Treatment
Lakhman, S. S., Ma, Q., & Morse, G. D. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.53 · Cited by 51
ADOLESCENT NICOTINE METABOLISM: ETHNORACIAL DIFFERENCES AMONG DEPENDENT SMOKERS
Moolchan, E. T., Franken, F. H., & Jaszyna-Gasior, M. (2006) · PubMed · doi:10.13016/ovfm-bldx · Cited by 48
Kaspera, R., Naraharisetti, S. B., Evangelista, E. A., Marciante, K. D., Psaty, B. M., & Totah, R. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.027 · Cited by 46
Jaja, C., Burke, W., Thummel, K. E., Edwards, K. L., & Veenstra, D. L. (2008) · Public Health Genomics · doi:10.1159/000113876 · Cited by 45
Specific human CYP 450 isoform metabolism of a pentachlorobiphenyl (PCB-IUPAC# 101)
McGraw, J. E., & Waller, D. P. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.122 · Cited by 45
Self-citationGenetic polymorphisms related to efficacy and overuse of triptans in chronic migraine
Gentile, G., Borro, M., Lala, N., Missori, S., Simmaco, M., & Martelletti, P. (2010) · The Journal of Headache and Pain · doi:10.1007/s10194-010-0241-0 · Cited by 44
Ramachandran, G., Ramesh, K., Kumar, A. K. H., Jagan, I., Vasantha, M., Padmapriyadarsini, C., Narendran, G., Rajasekaran, S., & Swaminathan, S. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp033 · Cited by 44
Gene–gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism
Ring, H. Z., Valdes, A. M., Nishita, D., Prasad, S., Jacob, P., Tyndale, R. F., Swan, G. E., & Benowitz, N. L. (2007) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000220560.59972.33 · Cited by 42
Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese
Guan, S., Huang, M., Chan, E., Chen, X., Duan, W., & Zhou, S. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.04.004 · Cited by 41
New CYP2A6 Gene Deletion and Conversion Variants in a Population of Black African Descent
Mwenifumbo, J. C., Zhou, Q., Benowitz, N. L., Sellers, E. M., & Tyndale, R. F. (2010) · Pharmacogenomics · doi:10.2217/pgs.09.144 · Cited by 38
Yi, B., Yang, J.-Y., & Yang, M. (2007) · Journal of Environmental Science and Health Part C · doi:10.1080/10590500701704037 · Cited by 20
Cytochrome P450 2C19 genetic polymorphisms in Ugandans
Miura, J., Obua, C., Abbo, C., Kaneko, S., & Tateishi, T. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0583-6 · Cited by 19
Novel SNPs in Cytochrome P450 Oxidoreductase
Hart, S. N., Li, Y., Nakamoto, K., Wesselman, C., & Zhong, X. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.322 · Cited by 19
McGraw, J., & Waller, D. (2009) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2008.08.008 · Cited by 13
Self-citationCoffee, Myocardial Infarction, and CYP Nomenclature
Ingelman‐Sundberg, M., Sim, S. C., & Nebert, D. W. (2006) · JAMA · doi:10.1001/jama.296.7.764-b · Cited by 10
Cited by
Zhou, Y., Ingelman‐Sundberg, M., & Lauschke, V. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.690 · Cited by 583
Applications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 354
Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy
Preissner, S. C., Hoffmann, M. F., Preissner, R., Dunkel, M., Gewiess, A., & Preissner, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082562 · Cited by 278
Metadata
- Authors
- McGraw, J., & Waller, D.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2012-01-31
- Volume
- 8
- Issue
- 3
- Pages
- 371-382
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2131319167
- Cited by
- 286
- References
- 71
- FWCI
- 24.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.